These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 34751183

  • 1. Epstein-Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes.
    Lindsay J, Othman J, Heldman MR, Slavin MA.
    Curr Opin Infect Dis; 2021 Dec 01; 34(6):635-645. PubMed ID: 34751183
    [Abstract] [Full Text] [Related]

  • 2. Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant.
    Lindsay J, Othman J, Yong MK, Ritchie D, Chee L, Tay K, Tio SY, Kerridge I, Fay K, Stevenson W, Arthur C, Chen SC, Kong DCM, Greenwood M, Pergam SA, Liu C, Slavin MA.
    Transpl Infect Dis; 2021 Oct 01; 23(5):e13719. PubMed ID: 34453768
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.
    Kalra A, Roessner C, Jupp J, Williamson T, Tellier R, Chaudhry A, Khan F, Taparia M, Jimenez-Zepeda VH, Stewart DA, Daly A, Storek J.
    Clin Transplant; 2018 Jan 01; 32(1):. PubMed ID: 29114932
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN, Lin J, Wang LJ, Li F, Li HH, Wang SH, Huang WR, Gao CJ, Yu L, Liu DH.
    Ann Hematol; 2019 Sep 01; 98(9):2163-2177. PubMed ID: 31243569
    [Abstract] [Full Text] [Related]

  • 12. The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review.
    AlDabbagh MA, Gitman MR, Kumar D, Humar A, Rotstein C, Husain S.
    Am J Transplant; 2017 Mar 01; 17(3):770-781. PubMed ID: 27545492
    [Abstract] [Full Text] [Related]

  • 13. The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients.
    Wareham NE, Mocroft A, Sengeløv H, Da Cunha-Bang C, Gustafsson F, Heilmann C, Iversen M, Kirkby NS, Rasmussen A, Sørensen SS, Lundgren JD, MATCH in PERSIMUNE study group.
    J Cancer Res Clin Oncol; 2018 Aug 01; 144(8):1569-1580. PubMed ID: 29804164
    [Abstract] [Full Text] [Related]

  • 14. A Focused Review of Epstein-Barr Virus Infections and PTLD in Pediatric Transplant Recipients: Guidance From the IPTA and ECIL Guidelines.
    Yamada M, L'Huillier AG, Green M.
    J Pediatric Infect Dis Soc; 2024 Feb 28; 13(Supplement_1):S31-S38. PubMed ID: 38417085
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Epstein-Barr Virus DNAemia and post-transplant lymphoproliferative disorder in pediatric solid organ transplant recipients.
    Chang YC, Young RR, Mavis AM, Chambers ET, Kirmani S, Kelly MS, Kalu IC, Smith MJ, Lugo DJ.
    PLoS One; 2022 Feb 28; 17(10):e0269766. PubMed ID: 36256635
    [Abstract] [Full Text] [Related]

  • 17. Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol.
    Nikiforow S, Whangbo JS, Reshef R, Tsai DE, Bunin N, Abu-Arja R, Mahadeo KM, Weng WK, Van Besien K, Loeb D, Nasta SD, Nemecek ER, Zhao W, Sun Y, Galderisi F, Wahlstrom J, Mehta A, Gamelin L, Dinavahi R, Prockop S.
    Blood Adv; 2024 Jun 25; 8(12):3001-3012. PubMed ID: 38625984
    [Abstract] [Full Text] [Related]

  • 18. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J, Einsele H, Gil L, Ljungman P.
    Transpl Infect Dis; 2009 Oct 25; 11(5):383-92. PubMed ID: 19558376
    [Abstract] [Full Text] [Related]

  • 19. EBV-specific cytotoxic T lymphocytes for refractory EBV-associated post-transplant lymphoproliferative disorder in solid organ transplant recipients: a systematic review.
    Liu JY, Zhang JM, Zhan HS, Sun LY, Wei L.
    Transpl Int; 2021 Dec 25; 34(12):2483-2493. PubMed ID: 34510581
    [Abstract] [Full Text] [Related]

  • 20. Who is the patient at risk for EBV reactivation and disease: expert opinion focused on post-transplant lymphoproliferative disorders following hematopoietic stem cell transplantation.
    Marjanska A, Styczynski J.
    Expert Opin Biol Ther; 2023 Dec 25; 23(6):539-552. PubMed ID: 36971380
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.